Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01820260 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 395
- Enrollment target
NCT01820260 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 395 participants.
The verdict
NCT01820260, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 395 participants
- Enrollment target
Study Summary
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle gel
Interventions
- DRUG placebo
- DRUG Ingenol mebutate gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 395 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01820260
The ClinicalTrials.gov registry entry for NCT01820260 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 395 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01820260 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01820260 about?
NCT01820260 is a clinical study titled "Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis". To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or 3 consecutive days compared to vehicle gel
What is the current status of trial NCT01820260?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 395 participants. The study started on 2013-04. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01820260?
The interventions under investigation include: placebo (DRUG), Ingenol mebutate gel (DRUG).
Who is sponsoring clinical trial NCT01820260?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.